Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has been assigned a consensus rating of “Buy” from the twenty analysts that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $79.38.
A number of research analysts have weighed in on RARE shares. Morgan Stanley raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $68.00 to $83.00 in a report on Wednesday, March 27th. BidaskClub raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 9th. Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, January 7th. Raymond James lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 2nd. Finally, SunTrust Banks lifted their target price on Ultragenyx Pharmaceutical to $71.00 and gave the company a “buy” rating in a report on Wednesday, January 23rd.
Shares of Ultragenyx Pharmaceutical stock opened at $64.43 on Monday. Ultragenyx Pharmaceutical has a 52-week low of $37.44 and a 52-week high of $90.98. The stock has a market capitalization of $3.30 billion, a P/E ratio of -8.72 and a beta of 2.22.
In other news, CFO Shalini Sharp sold 14,800 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $70.00, for a total transaction of $1,036,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of RARE. Exane Derivatives purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $36,000. Meeder Asset Management Inc. lifted its position in Ultragenyx Pharmaceutical by 321.1% in the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 456 shares during the last quarter. Bank of Montreal Can lifted its position in Ultragenyx Pharmaceutical by 100.9% in the 4th quarter. Bank of Montreal Can now owns 1,079 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 542 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $55,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Ultragenyx Pharmaceutical by 16.6% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,924 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 274 shares during the last quarter. 98.62% of the stock is owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.